ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2568

The Osteoimmunological Mechanistic Basis of Low-Dose Radiotherapy in TNF Driven Arthritis

Lisa Deloch1, Anja Derer1, Axel J. Hueber2, Barbara Happich3, Rainer Fietkau1, Benjamin Frey1 and Udo S. Gaipl1, 1Department of Radiation Oncology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Department of Internal Medicine 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 3Internal Medicine 3, Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Animal models, bone biology, inflammation and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 10, 2015

Title: Rheumatoid Arthritis - Animal Models Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Today many treatment options for Rheumatoid Arthritis (RA) and degenerative inflammatory musculoskeletal diseases are available, however, not all patients respond properly or have to reduce or stop their medication due to adverse reactions. In such cases treatment with low dose-radiotherapy (LD-RT) with X-rays can be beneficial to attenuate inflammation, reduce pain and improve the quality of life, as suggested by studies by Ott et al. (2012-2014) and Seegenschmiedt et al. (1998). Preclinical in vitro models have revealed that doses of X-ray ranging from 0.1 Gray (Gy) to 1.0 Gy have an impact on immune cells and reduce the inflammatory phenotype of endothelial cells, neutrophils, and macrophages. A dose of 0.5 Gy has been shown to be the most efficient. Even though these mechanisms are well known and accepted, health care professionals and patients often refrain from low LD-RT. The main reasons for that are fear of radiation, lack of randomized trials and lack of in vivo examinations with inflammatory animal models. We therefore aimed to examine the impact of local LD-RT with 0.5 Gy on inflammation and bone homeostasis in human TNF-α transgenic (hTNF-αtg) mice.

Methods: Inflamed joints of hTNFα tg mice were locally irradiated (0.5 Gy, 250 kV, 15mA) and monitored over a time course of 30 days. Afterwards, paw sections were analyzed using histomorphological methods and the OsteoMeasure™ Software. In an ex vivo setting, we investigated the effects of LD-RT on bone marrow-derived osteoclasts (OC) of hTNFαtg mice as well as on murine and human fibroblast-like synoviocytes (FLS) using qPCR, ELISA and flow cytometry.

Results: A significant improvement of grip strength over 30 days in mice treated locally with 1x 0.5 Gy of X-rays was observed. Further histological analysis of irradiated paws showed a significant reduction of the inflammatory area as identified by decrease of leukocyte infiltration, reduction of bone loss, and OC numbers in comparison to mock treated control animals. Ex vivo differentiation of hTNFαtg mice derived OCs was also significantly reduced after exposure to X-rays in the dose range of 0.5 to 2.0 Gy. Further, OC function seems to be down-regulated after an irradiation with 2x 0.5 Gy as indicated by qPCR analysis. Irradiation of human RA FLS resulted in a dose-dependent reduction of cell growth and increased numbers of apoptotic cells.

Conclusion: On a mechanistic preclinical osteoimmunlogical basis our findings support that LD-RT can influence TNF dependent arthritis. The results from our OC experiments further imply that LD-RT does not only have a considerably decelerating effect on inflammation, but also on bone erosion. Future placebo controlled studies in humans need to address its effect in RA patients.

Acknowledgement: This project is supported by the German Federal Ministry of Education and Research (GREWIS, 02NUK017G).


Disclosure: L. Deloch, None; A. Derer, None; A. J. Hueber, None; B. Happich, None; R. Fietkau, None; B. Frey, None; U. S. Gaipl, None.

To cite this abstract in AMA style:

Deloch L, Derer A, Hueber AJ, Happich B, Fietkau R, Frey B, Gaipl US. The Osteoimmunological Mechanistic Basis of Low-Dose Radiotherapy in TNF Driven Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-osteoimmunological-mechanistic-basis-of-low-dose-radiotherapy-in-tnf-driven-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-osteoimmunological-mechanistic-basis-of-low-dose-radiotherapy-in-tnf-driven-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology